About recombina nt factor viii
Recombinant factor VIII clotting factor
Used for
- Prevention and treatment of bleeding in hemophilia A
- Bleeding control during surgery in hemophilia A
Usual adult dose
Intravenous dose is based on body weight, target clotting-factor level, and bleeding severity; commonly 20–50 IU/kg per dose.
Usual dose in children
Intravenous dose is individualized by weight, target clotting-factor level, and bleeding severity; commonly 20–50 IU/kg per dose.
Common side effects
- Headache
- Fever
- Injection-site reactions
- Development of factor VIII inhibitors
Important warnings
- Seek urgent care for severe allergic reactions, including breathing difficulty or facial swelling.
- Factor VIII inhibitors can reduce treatment effectiveness; monitoring is needed.
- Use only the prescribed product and follow its reconstitution and infusion instructions.
Pregnancy
Human pregnancy data are limited; use when clinically needed under specialist supervision.
Breastfeeding
There are no adequate data on use during breastfeeding; discuss treatment with a clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.